Cargando…

Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial

We assessed the impact of mHealth on Pap test screening uptake and also determined the factors that affect screening uptake among women in Lagos, Nigeria. MATERIALS AND METHODS: A randomized controlled trial was carried out among women in two tertiary health institutions in Lagos, Nigeria, between J...

Descripción completa

Detalles Bibliográficos
Autores principales: Okunade, Kehinde S., Soibi-Harry, Adaiah, John-Olabode, Sarah, Adejimi, Adebola A., Allsop, Matthew J., Onyeka, Tonia C., Akaba, Godwin O., Oshodi, Yusuf A., Salako, Omolola, Ugwu, Aloy O., Adefemi, Ayodeji, Anorlu, Rose I., Berek, Jonathan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478387/
https://www.ncbi.nlm.nih.gov/pubmed/34554814
http://dx.doi.org/10.1200/GO.21.00258
_version_ 1784576045435846656
author Okunade, Kehinde S.
Soibi-Harry, Adaiah
John-Olabode, Sarah
Adejimi, Adebola A.
Allsop, Matthew J.
Onyeka, Tonia C.
Akaba, Godwin O.
Oshodi, Yusuf A.
Salako, Omolola
Ugwu, Aloy O.
Adefemi, Ayodeji
Anorlu, Rose I.
Berek, Jonathan S.
author_facet Okunade, Kehinde S.
Soibi-Harry, Adaiah
John-Olabode, Sarah
Adejimi, Adebola A.
Allsop, Matthew J.
Onyeka, Tonia C.
Akaba, Godwin O.
Oshodi, Yusuf A.
Salako, Omolola
Ugwu, Aloy O.
Adefemi, Ayodeji
Anorlu, Rose I.
Berek, Jonathan S.
author_sort Okunade, Kehinde S.
collection PubMed
description We assessed the impact of mHealth on Pap test screening uptake and also determined the factors that affect screening uptake among women in Lagos, Nigeria. MATERIALS AND METHODS: A randomized controlled trial was carried out among women in two tertiary health institutions in Lagos, Nigeria, between July 2020 and March 2021. Participants were randomly assigned to either a text message (mHealth) intervention or usual care arm. The main study outcome was the uptake of Pap smear testing within 6 months of enrollment in the study. We tested the associations between two groups of continuous variables using the unpooled independent-sample t-test (normal distribution) and that of two groups of categorical variables with the chi-square (χ(2)) test. Using a multinomial logistic regression model, we adjusted for relevant sociodemographic and clinical predictors of uptake of Pap smear screening. Statistical significance was defined as P < .05. RESULTS: There was a significantly higher rate of uptake of Pap smear screening among women in the mHealth arm compared with those in the usual care arm (51.0% v 35.7%, P = .031). Following adjustment in the final multivariate model, level of income (odds ratio [OR] = 5.13, 95% CI, 1.55 to 16.95), awareness of Pap smear (OR = 16.26; 95% CI, 2.49 to 76.64), General Outpatient clinic attendance, and introduction of mHealth intervention during follow-up (OR = 4.36; 95% CI, 1.44 to 13.22) were the independent predictors of Pap smear uptake. CONCLUSION: The use of mHealth technologies intervention via short-text message services is a feasible solution for cervical cancer prevention in low- and middle-income countries, and thus, the widespread use of mHealth services by health care providers and policymakers could contribute to the implementation of cervical cancer prevention services in Nigeria and in the settings of other low- and middle-income countries.
format Online
Article
Text
id pubmed-8478387
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-84783872021-09-29 Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial Okunade, Kehinde S. Soibi-Harry, Adaiah John-Olabode, Sarah Adejimi, Adebola A. Allsop, Matthew J. Onyeka, Tonia C. Akaba, Godwin O. Oshodi, Yusuf A. Salako, Omolola Ugwu, Aloy O. Adefemi, Ayodeji Anorlu, Rose I. Berek, Jonathan S. JCO Glob Oncol ORIGINAL REPORTS We assessed the impact of mHealth on Pap test screening uptake and also determined the factors that affect screening uptake among women in Lagos, Nigeria. MATERIALS AND METHODS: A randomized controlled trial was carried out among women in two tertiary health institutions in Lagos, Nigeria, between July 2020 and March 2021. Participants were randomly assigned to either a text message (mHealth) intervention or usual care arm. The main study outcome was the uptake of Pap smear testing within 6 months of enrollment in the study. We tested the associations between two groups of continuous variables using the unpooled independent-sample t-test (normal distribution) and that of two groups of categorical variables with the chi-square (χ(2)) test. Using a multinomial logistic regression model, we adjusted for relevant sociodemographic and clinical predictors of uptake of Pap smear screening. Statistical significance was defined as P < .05. RESULTS: There was a significantly higher rate of uptake of Pap smear screening among women in the mHealth arm compared with those in the usual care arm (51.0% v 35.7%, P = .031). Following adjustment in the final multivariate model, level of income (odds ratio [OR] = 5.13, 95% CI, 1.55 to 16.95), awareness of Pap smear (OR = 16.26; 95% CI, 2.49 to 76.64), General Outpatient clinic attendance, and introduction of mHealth intervention during follow-up (OR = 4.36; 95% CI, 1.44 to 13.22) were the independent predictors of Pap smear uptake. CONCLUSION: The use of mHealth technologies intervention via short-text message services is a feasible solution for cervical cancer prevention in low- and middle-income countries, and thus, the widespread use of mHealth services by health care providers and policymakers could contribute to the implementation of cervical cancer prevention services in Nigeria and in the settings of other low- and middle-income countries. Wolters Kluwer Health 2021-09-23 /pmc/articles/PMC8478387/ /pubmed/34554814 http://dx.doi.org/10.1200/GO.21.00258 Text en © 2021 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle ORIGINAL REPORTS
Okunade, Kehinde S.
Soibi-Harry, Adaiah
John-Olabode, Sarah
Adejimi, Adebola A.
Allsop, Matthew J.
Onyeka, Tonia C.
Akaba, Godwin O.
Oshodi, Yusuf A.
Salako, Omolola
Ugwu, Aloy O.
Adefemi, Ayodeji
Anorlu, Rose I.
Berek, Jonathan S.
Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial
title Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial
title_full Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial
title_fullStr Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial
title_full_unstemmed Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial
title_short Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial
title_sort impact of mobile technologies on cervical cancer screening practices in lagos, nigeria (mhealth-cervix): a randomized controlled trial
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478387/
https://www.ncbi.nlm.nih.gov/pubmed/34554814
http://dx.doi.org/10.1200/GO.21.00258
work_keys_str_mv AT okunadekehindes impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT soibiharryadaiah impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT johnolabodesarah impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT adejimiadebolaa impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT allsopmatthewj impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT onyekatoniac impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT akabagodwino impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT oshodiyusufa impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT salakoomolola impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT ugwualoyo impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT adefemiayodeji impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT anorlurosei impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial
AT berekjonathans impactofmobiletechnologiesoncervicalcancerscreeningpracticesinlagosnigeriamhealthcervixarandomizedcontrolledtrial